Your browser doesn't support javascript.
español english

Biblioteca Virtual en Salud

Hipertensión

Home > Búsqueda > ()
Búsqueda Avanzada | Localizar descriptor de asunto
XML
Imprimir Exportar

Formato de exportación:

Exportar

Email
Adicionar mas contactos
| |

The effect of infliximab, cyclosporine A and recombinant IL-10 on vitreous cytokine levels in experimental autoimmune uveitis.

Demir, Tamer; Gödekmerdan, Ahmet; Balbaba, Mehmet; Türkçüoglu, Peykan; Ilhan, Fulya; Demir, Nesrin.
Indian J Ophthalmol ; 2006 Dec; 54(4): 241-5
Artículo en Inglés | IMSEAR | ID: sea-71034

BACKGROUND:

To identify the effect of infliximab, cyclosporine A and recombinant IL-10 in experimental autoimmune uveitis. MATERIALS AND

METHODS:

Sixty male rats were assigned to five groups of 12 each. All the groups (except the control group) were administered 30 microg retinal-S antigen intraperitoneally. On the 14th day, after confirmation of uveitis with histopathological study, daily cyclosporine A injection was given in cyclosporine A treatment group and physiological serum in the uveitis-induced placebo treatment and control groups. In the infliximab treatment group, infliximab was administered on the 14th, 15th, 17th, 19th and 21st days. In the recombinant IL-10 treatment group, three doses of recombinant IL-10 were given four hours and a half hours before and eight hours after retinal-S antigen administration. On the 21st day of the study, all rats were sacrificed and vitreous cytokine levels (IL-1, IL-6, IL-8 and TNF-alpha) were studied with ELISA.

RESULTS:

In the treatment groups, cytokine levels (IL-1, IL-6 and TNF-alpha) were significantly lower than the uveitis-induced placebo treatment group. Compared with the control group, there was no significant difference with respect to TNF-alpha and IL-8 in the infliximab treatment group; IL-8 in the cyclosporine A treatment group; IL-6 and IL-8 in the recombinant IL-10 treatment group. The drugs used did not significantly differ in respect to their effects on vitreous IL-6, IL-8 and TNF-alpha levels.

CONCLUSION:

Cyclosporine A, infliximab and recombinant IL-10 reduce the vitreous cytokines levels. Among these drugs, recombinant IL-10, which is still in its experimental phase, might be considered as a new therapeutic agent.

Asunto(s)

Animales Antiinflamatorios/administración & dosificación Anticuerpos Monoclonales/administración & dosificación Arrestina/toxicidad Enfermedades Autoinmunes/tratamiento farmacológico Biomarcadores/metabolismo Ciclosporina/administración & dosificación Citocinas/metabolismo Modelos Animales de Enfermedad Estudios de Seguimiento Inmunosupresores/administración & dosificación Inyecciones Intraperitoneales Interleucina-10/administración & dosificación Masculino Ratas Ratas Endogámicas Lew Proteínas Recombinantes Resultado del Tratamiento Factor de Necrosis Tumoral alfa Uveítis/tratamiento farmacológico Cuerpo Vítreo/efectos de los fármacos
powered by iAHx-2.18-89 Biblioteca Virtual en Salud
pagina inicial | acerca del Portal